ReviewEuropean journal of pediatrics2026
Sequential emergence of hematuria and proteinuria in autosomal dominant Alport syndrome: a pathophysiological perspective.
Review in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant Alport syndrome (ADAS) is characterized by pathogenic variants in COL4A3 or COL4A4 and typically presents with persistent microscopic hematuria, while clinically detectable proteinuria often emerges later in the disease course. The pathophysiological basis for this sequential pattern remains incompletely understood. From a structural and biophysical perspective, erythrocyte impermeability represents a more stringent requirement of the glomerular filtration barrier than protein impermeability. Glomerular basement membrane thinning alone is unlikely to permit red blood cell passage, suggesting that microscopic hematuria may reflect focal full-thickness disruption of the filtration barrier at a limited number of sites. In contrast, clinically detectable proteinuria may require a substantially greater reduction in effective filtration barrier integrity and surface area, potentially involving both glomerular basement membrane and podocyte injury. We therefore propose that the common clinical sequence of isolated hematuria followed by proteinuria can be interpreted as a continuum of increasing glomerular fragility in a genetically vulnerable filtration barrier. Although alternative explanations, including age-dependent expression and variable penetrance, should be considered, this model offers a plausible pathophysiological framework for understanding disease progression.
conclusionPersistent hematuria in children with ADAS may therefore represent an early marker of ongoing glomerular vulnerability rather than a completely benign finding, highlighting the importance of longitudinal monitoring before the development of overt proteinuria. WHAT IS KNOWN: • Hematuria is usually the earliest manifestation of autosomal dominant Alport syndrome. • Proteinuria is associated with a higher risk of kidney disease progression. WHAT IS NEW: • Sequential emergence of hematuria and proteinuria may reflect progressive impairment of the glomerular filtration barrier in autosomal dominant Alport syndrome. • A pathophysiological model based on injury to the three components of the glomerular filtration barrier-the endothelium, glomerular basement membrane, and podocytes-is proposed.
Indexed as
Identifiers
42334616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.